Description
Title: Adult Patients with Sickle Cell Anaemia: A Double-Blind Clinical Trial of Arginine Supplementation
Abstract: Background. In Brazil, the most common monogenic disease is sickle cell anemia (SCA). Haemoglobin S (HbS), which changes the morphology of red blood cells, is produced in SCA. Free Hb and free radicals degrade nitric oxide (NO) and release arginase during intravascular hemolysis, which lowers arginine levels. This decline results in less NO (vasodilator) synthesis because arginine serves as a substrate for NO formation. Hydroxyurea (HU) is used in the treatment of SCA to maintain high levels of foetal hemoglobin (HbF) and to lower HbS to prevent hemolytic episodes. Objective. to evaluate L-effectiveness arginine’s in treating SCA patients when used as an adjuvant. Setting: Brazil’s State Blood Center in Ceará. Methods. At the State Blood Center of Cear’a, adults with SCA who were continuously receiving HU participated in this randomized, double-blind clinical study. 25 patients received HU + L-arginine (500mg) as part of the clinical study, while 25 patients received HU + placebo. Four months were spent on the treatment. The following levels were measured in the lab: (1) complete blood count, (2) nitrite + nitrate, (3) HbF, and (4) reticulocytes. The haematologist who carried out the clinical trials. Nitrite and pain were the primary outcome indicators. Results. Utilizing a pain frequency scale by day, week, and month, statistical analysis revealed that the study group’s NO levels had increased and that pain frequency had decreased. The levels of nitrite plus nitrate in the group receiving placebo plus HU did not change over the course of the evaluation (38.27 17.27 mg/L, 39.49 12.84 mg/L, 34.45 11.25 mg/L, p >0.05), but in the patients receiving supplementation with L-arginine plus HU, a significant rise in nitrite plus nitrate levels was seen between M0 and M4 (36.55 It is significant to note that the increase in nitrite plus nitrate levels didn’t appear until the fourth month of the treatment group’s patients’ follow-up, indicating that at least four months of L-arginine supplementation are required to see an increase in these metabolites in the serum. Conclusion. Patients’ quality of life may be enhanced by the use of L-arginine as a coadjuvant in the treatment of sickle cell anemia by acting as a potential tool for pain management.
Paper Quality: SCOPUS / Web of Science Level Research Paper
Subject: Medicine
Sub Category: Hematology
Writer Experience: 20+ Years
Plagiarism Report: Turnitin Plagiarism Report will be less than 10%
Restriction: Only one author may purchase a single paper. The paper will then indicate that it is out of stock.
What will I get after the purchase?
A turnitin plagiarism report of less than 10% in a pdf file and a full research paper in a word document.
In case you have any questions related to this research paper, please feel free to call/ WhatsApp on +919726999915
Reviews
There are no reviews yet.